{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T12:36:26Z","timestamp":1789389386649,"version":"build-2803163510"},"reference-count":48,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.urolonc.2014.11.020","type":"journal-article","created":{"date-parts":[[2015,1,14]],"date-time":"2015-01-14T10:11:52Z","timestamp":1421230312000},"page":"217-225","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Chemotherapy and novel therapeutics before radical prostatectomy for high-risk clinically localized prostate cancer"],"prefix":"10.1016","volume":"33","author":[{"given":"Eugene K.","family":"Cha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Eastham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2014.11.020_bib1","first-page":"9","article-title":"Cancer statistics, 2014","volume":"64","author":"Siegel","year":"2014","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urolonc.2014.11.020_bib2","doi-asserted-by":"crossref","first-page":"686","DOI":"10.6004\/jnccn.2014.0072","article-title":"Prostate cancer, version 2.2014","volume":"12","author":"Mohler","year":"2014","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.urolonc.2014.11.020_bib3","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.juro.2007.03.105","article-title":"Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods","volume":"178","author":"Yossepowitch","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2014.11.020_bib4","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.juro.2006.08.057","article-title":"Changing nature of high risk patients undergoing radical prostatectomy","volume":"177","author":"Kane","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2014.11.020_bib5","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0140-6736(02)09408-4","article-title":"Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial","volume":"360","author":"Bolla","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.urolonc.2014.11.020_bib6","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1464-410X.2009.08698.x","article-title":"Long-term follow-up of 3-month neoadjuvant hormone therapy before radical prostatectomy in a randomized trial","volume":"105","author":"Yee","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2014.11.020_bib7","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0022-5347(05)65393-1","article-title":"Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results","volume":"167","author":"Soloway","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2014.11.020_bib8","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1097\/01.ju.0000081404.98273.fd","article-title":"Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy","volume":"170","author":"Klotz","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2014.11.020_bib9","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","article-title":"Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes","volume":"30","author":"von Minckwitz","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2014.11.020_bib10","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2014.11.020_bib11","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1200\/JCO.2007.15.0235","article-title":"Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27","volume":"26","author":"Rastogi","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2014.11.020_bib12","doi-asserted-by":"crossref","unstructured":"International Collaboration of Trialists; Medical Research Council Advanced Bladder Cancer Working Party; European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group; Australian Bladder Cancer Study Group; National Cancer Institute of Canada Clinical Trials Group, et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol 2011;29:2171\u20132177.","DOI":"10.1200\/JCO.2010.32.3139"},{"key":"10.1016\/j.urolonc.2014.11.020_bib13","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1056\/NEJMoa040694","article-title":"Preoperative versus postoperative chemoradiotherapy for rectal cancer","volume":"351","author":"Sauer","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2014.11.020_bib14","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","article-title":"Preoperative chemoradiotherapy for esophageal or junctional cancer","volume":"366","author":"van Hagen","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2014.11.020_bib15","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","volume":"351","author":"Petrylak","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2014.11.020_bib16","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2014.11.020_bib17","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.urolonc.2014.11.020_bib18","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.urology.2004.01.040","article-title":"Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer","volume":"63","author":"Dreicer","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2014.11.020_bib19","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1002\/cncr.22897","article-title":"Neoadjuvant docetaxel treatment for locally advanced prostate cancer: a clinicopathologic study","volume":"110","author":"Magi-Galluzzi","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2014.11.020_bib20","doi-asserted-by":"crossref","first-page":"5233","DOI":"10.1158\/1078-0432.CCR-05-0299","article-title":"Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer","volume":"11","author":"Febbo","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2014.11.020_bib21","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.juro.2007.10.064","article-title":"Neoadjuvant docetaxel and capecitabine in patients with high risk prostate cancer","volume":"179","author":"Friedman","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2014.11.020_bib22","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/j.juro.2008.11.121","article-title":"Phase II trial of neoadjuvant nab-paclitaxel in high risk patients with prostate cancer undergoing radical prostatectomy","volume":"181","author":"Shepard","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2014.11.020_bib23","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1002\/cncr.24960","article-title":"Phase 1\/2 study of preoperative docetaxel and mitoxantrone for high-risk prostate cancer","volume":"116","author":"Garzotto","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2014.11.020_bib24","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1200\/JCO.2000.18.5.1050","article-title":"Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results","volume":"18","author":"Pettaway","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2014.11.020_bib25","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0090-4295(00)00914-6","article-title":"Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer","volume":"57","author":"Clark","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2014.11.020_bib26","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1097\/01.ju.0000108122.36893.5a","article-title":"Feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy for patients with high risk or locally advanced prostate cancer: results of a phase I\/II study","volume":"171","author":"Konety","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2014.11.020_bib27","article-title":"Long term oncologic outcomes of a Phase II trial of neoadjuvant chemohormonal therapy followed by radical prostatectomy for patients with clinically localized, high-risk prostate cancer","author":"Silberstein","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2014.11.020_bib28","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1464-410X.2007.06760.x","article-title":"Long-term follow-up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer","volume":"100","author":"Prayer-Galetti","year":"2007","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2014.11.020_bib29","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.juro.2008.04.012","article-title":"Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer","volume":"180","author":"Chi","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2014.11.020_bib30","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.urology.2007.08.060","article-title":"Neoadjuvant chemohormonal therapy in poor-prognosis localized prostate cancer","volume":"71","author":"Sella","year":"2008","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2014.11.020_bib31","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/sj.bjc.6605320","article-title":"Phase II trial of short-term neoadjuvant docetaxel and complete androgen blockade in high-risk prostate cancer","volume":"101","author":"Mellado","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urolonc.2014.11.020_bib32","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.juro.2011.04.087","article-title":"A phase II clinical trial of neoadjuvant ketoconazole and docetaxel chemotherapy before radical prostatectomy in high risk patients","volume":"186","author":"Womble","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2014.11.020_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1477-7819-10-1","volume":"10","author":"Narita","year":"2012","journal-title":"World J Surg Oncol"},{"issue":"Suppl. 1","key":"10.1016\/j.urolonc.2014.11.020_bib34","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.urology.2003.09.052","article-title":"Cancer, Leukemia Group B. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease","volume":"62","author":"Eastham","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2014.11.020_bib35","unstructured":"Cancer and Leukemia Group B. Surgery with or without docetaxel and leuprolide or goserelin in treating patients with high-risk localized prostate cancer [ClinicalTrials.gov identifier NCT00430183]. US National Institutes of Health, ClinicalTrials.gov [online]. http:\/\/www.clinicaltrials.gov."},{"key":"10.1016\/j.urolonc.2014.11.020_bib36","doi-asserted-by":"crossref","first-page":"4777","DOI":"10.1002\/cncr.27416","article-title":"Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial","volume":"118","author":"Ross","year":"2012","journal-title":"Cancer"},{"issue":"suppl.","key":"10.1016\/j.urolonc.2014.11.020_bib37","first-page":"7","article-title":"Neoadjuvant trial of sunitinib malate and androgen ablation (ADT) in patients with localized prostate cancer (PCa) at high risk for recurrence","volume":"29","author":"Zurita","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2014.11.020_bib38","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1002\/cncr.24092","article-title":"Phase II trial of neoadjuvant docetaxel and gefitinib followed by radical prostatectomy in patients with high-risk, locally advanced prostate cancer","volume":"115","author":"Vuky","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2014.11.020_bib39","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1158\/1078-0432.CCR-05-1652","article-title":"Application of oligonucleotide microarrays to assess the biological effects of neoadjuvant imatinib mesylate treatment for localized prostate cancer","volume":"12","author":"Febbo","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2014.11.020_bib40","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.juro.2008.09.006","article-title":"Neoadjuvant platelet derived growth factor receptor inhibitor therapy combined with docetaxel and androgen ablation for high risk localized prostate cancer","volume":"181","author":"Mathew","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2014.11.020_bib41","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1093\/jnci\/dji252","article-title":"A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2\u05f3-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer","volume":"97","author":"Chi","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.urolonc.2014.11.020_bib42","unstructured":"University of British Columbia. Study of OGX-011 given prior to radical prostatectomy in patients with localized prostate cancer. [ClinicalTrials.gov identifier NCT00138918]. US National Institutes of Health, ClinicalTrials.gov [online]. http:\/\/www.clinicaltrials.gov."},{"key":"10.1016\/j.urolonc.2014.11.020_bib43","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"issue":"suppl.","key":"10.1016\/j.urolonc.2014.11.020_bib44","first-page":"30","article-title":"Neoadjuvant sipuleucel-T in localized prostate cancer: Effects on immune cells within the prostate tumor microenvironment","author":"Fong","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2014.11.020_bib45","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1200\/JCO.2007.13.4197","article-title":"Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial","volume":"26","author":"Flaig","year":"2008","journal-title":"J Clin Oncol"},{"issue":"suppl 5","key":"10.1016\/j.urolonc.2014.11.020_bib46","article-title":"The impact of neoadjuvant weekly ixabepilone for high-risk prostate cancer: a phase I\/II clinical trial","volume":"30","author":"Layton","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2014.11.020_bib47","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S0090-4295(02)02519-0","article-title":"Neoadjuvant docetaxel and estramustine chemotherapy in high-risk\/locallyadvanced prostate cancer","volume":"61","author":"Hussain","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2014.11.020_bib48","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1634\/theoncologist.2011-0234","article-title":"Phase II trial of neoadjuvant docetaxel and CG1940\/CG8711 followed by radical prostatectomy in patients with high-risk clinically localized prostate cancer","volume":"18","author":"Vuky","year":"2013","journal-title":"Oncologist"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107814391400444X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107814391400444X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T11:31:53Z","timestamp":1776079913000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S107814391400444X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S107814391400444X"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2014.11.020","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chemotherapy and novel therapeutics before radical prostatectomy for high-risk clinically localized prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2014.11.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}